Novabay Pharmaceuticals Inc Recommandation moyenne
Quel est le Recommandation moyenne de Novabay Pharmaceuticals Inc?
Le Recommandation moyenne de Novabay Pharmaceuticals Inc est 1.00
Quelle est la définition de Recommandation moyenne?
La moyenne recommandée est la moyenne des évaluations des actions par les analystes allant de 1,0 (achat fort) à 5,0 (vente forte).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommandation moyenne des entreprises dans Health Care secteur sur NYSEMKT par rapport à Novabay Pharmaceuticals Inc
Que fait Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Entreprises avec recommandation moyenne similaire à Novabay Pharmaceuticals Inc
- Novabay Pharmaceuticals Inc a Recommandation moyenne de 1.00
- JOYY Inc a Recommandation moyenne de 1.05
- Honda Motor a Recommandation moyenne de 1.06
- Ares Capital Corp a Recommandation moyenne de 1.07
- Petroleo Brasileiro S.A. Petrobras a Recommandation moyenne de 1.08
- VNET Inc a Recommandation moyenne de 1.08
- Rocket Pharmaceuticals Inc a Recommandation moyenne de 1.08